Display options
Cite
Pandey S, Singh S, Anang V, et al. Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth Metastasis. 2015;8:25-34doi: 10.4137/CGM.S24314.
Pandey, S., Singh, S., Anang, V., Bhatt, A. N., Natarajan, K., & Dwarakanath, B. S. (2015). Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer growth and metastasis, 825-34. https://doi.org/10.4137/CGM.S24314
Pandey, Sanjay, et al. "Pattern Recognition Receptors in Cancer Progression and Metastasis." Cancer growth and metastasis vol. 8 (2015): 25-34. doi: https://doi.org/10.4137/CGM.S24314
Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth Metastasis. 2015 Jul 23;8:25-34. doi: 10.4137/CGM.S24314. eCollection 2015. PMID: 26279628; PMCID: PMC4514171.
Copy Download .nbib Format: NLM
Share it on

Cancer Growth Metastasis. 2015 Jul 23;8:25-34. doi: 10.4137/CGM.S24314. eCollection 2015.

Pattern Recognition Receptors in Cancer Progression and Metastasis.

Cancer growth and metastasis

Sanjay Pandey, Saurabh Singh, Vandana Anang, Anant N Bhatt, K Natarajan, Bilikere S Dwarakanath

Affiliations

  1. Institute of Nuclear Medicine and Allied Sciences, Brig. S.K. Mazumdar Road, Delhi, India. ; Dr B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India.
  2. Institute of Nuclear Medicine and Allied Sciences, Brig. S.K. Mazumdar Road, Delhi, India.
  3. Dr B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India.

PMID: 26279628 PMCID: PMC4514171 DOI: 10.4137/CGM.S24314

Abstract

The innate immune system is an integral component of the inflammatory response to pathophysiological stimuli. Toll-like receptors (TLRs) and inflammasomes are the major sensors and pattern recognition receptors (PRRs) of the innate immune system that activate stimulus (signal)-specific pro-inflammatory responses. Chronic activation of PRRs has been found to be associated with the aggressiveness of various cancers and poor prognosis. Involvement of PRRs was earlier considered to be limited to infection- and injury-driven carcinogenesis, where they are activated by pathogenic ligands. With the recognition of damage-associated molecular patterns (DAMPs) as ligands of PRRs, the role of PRRs in carcinogenesis has also been implicated in other non-pathogen-driven neoplasms. Dying (apoptotic or necrotic) cells shed a plethora of DAMPs causing persistent activation of PRRs, leading to chronic inflammation and carcinogenesis. Such chronic activation of TLRs promotes tumor cell proliferation and enhances tumor cell invasion and metastasis by regulating pro-inflammatory cytokines, metalloproteinases, and integrins. Due to the decisive role of PRRs in carcinogenesis, targeting PRRs appears to be an effective cancer-preventive strategy. This review provides a brief account on the association of PRRs with various cancers and their role in carcinogenesis.

Keywords: HMGB1; damage-associated molecular patterns (DAMPs); inflammasome; pattern recognition receptors (PRRs); toll-like receptors (TLRs)

References

  1. Front Immunol. 2013 Jan 08;3:414 - PubMed
  2. J Biol Chem. 2002 Apr 26;277(17):15028-34 - PubMed
  3. J Immunol. 2013 Apr 1;190(7):3500-9 - PubMed
  4. Trends Immunol. 2011 Aug;32(8):373-9 - PubMed
  5. Inflamm Bowel Dis. 2011 Jul;17(7):1464-73 - PubMed
  6. Nat Cell Biol. 2014 Dec;16(12 ):1238-48 - PubMed
  7. Mediators Inflamm. 2013;2013:654963 - PubMed
  8. Nat Immunol. 2010 May;11(5):373-84 - PubMed
  9. Core Evid. 2008 Feb 29;2(3):199-207 - PubMed
  10. J Clin Invest. 2008 Feb;118(2):545-59 - PubMed
  11. J Autoimmun. 2009 May-Jun;32(3-4):172-7 - PubMed
  12. Curr Mol Med. 2014 May;14(4):423-31 - PubMed
  13. Front Immunol. 2014 Jul 31;5:367 - PubMed
  14. Science. 2007 Jul 6;317(5834):121-4 - PubMed
  15. Immunol Rev. 2009 Jan;227(1):95-105 - PubMed
  16. J Immunol. 2005 Apr 15;174(8):5016-23 - PubMed
  17. J Leukoc Biol. 2009 Sep;86(3):557-66 - PubMed
  18. J Hematol Oncol. 2014 Aug 12;7:57 - PubMed
  19. Clin Cancer Res. 2011 Mar 15;17(6):1502-8 - PubMed
  20. Int J Cancer. 2011 Sep 1;129(5):1116-25 - PubMed
  21. Int J Inflam. 2012;2012:504128 - PubMed
  22. Am J Pathol. 2012 Aug;181(2):380-7 - PubMed
  23. Carcinogenesis. 2012 Jun;33(6):1231-8 - PubMed
  24. Nat Med. 2012 Aug;18(8):1286-90 - PubMed
  25. FEBS Lett. 2011 Jun 6;585(11):1568-72 - PubMed
  26. Front Immunol. 2014 Jul 15;5:334 - PubMed
  27. Protein Cell. 2014 Jan;5(1):12-20 - PubMed
  28. Cancer Metastasis Rev. 2010 Jun;29(2):317-29 - PubMed
  29. Cell Signal. 2009 May;21(5):665-74 - PubMed
  30. Cancer Lett. 2012 Jan 1;314(1):24-33 - PubMed
  31. Biochim Biophys Acta. 2013 Apr;1835(2):144-54 - PubMed
  32. J Clin Oncol. 2006 Apr 20;24(12):1910-6 - PubMed
  33. Front Immunol. 2014 Oct 20;5:429 - PubMed
  34. Eur J Immunol. 2004 Feb;34(2):558-64 - PubMed
  35. Nat Genet. 2009 Jan;41(1):71-6 - PubMed
  36. Cell. 2010 Mar 19;140(6):805-20 - PubMed
  37. Science. 2012 Aug 31;337(6098):1111-5 - PubMed
  38. Cancer Invest. 2008 Oct;26(8):816-21 - PubMed
  39. Cancer Cell. 2012 Apr 17;21(4):504-16 - PubMed
  40. Oral Oncol. 2015 Jan;51(1):96-102 - PubMed
  41. Mol Cancer Ther. 2014 Mar;13(3):606-16 - PubMed
  42. Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1167-79 - PubMed
  43. Mol Oncol. 2015 Jun;9(6):1194-206 - PubMed
  44. Nature. 2006 Mar 9;440(7081):237-41 - PubMed
  45. Science. 2003 Jun 6;300(5625):1524-5 - PubMed
  46. Cancer Res. 2006 Apr 1;66(7):3859-68 - PubMed
  47. J Transl Med. 2012 Mar 20;10:52 - PubMed
  48. Am J Hum Genet. 2008 May;82(5):1202-10 - PubMed
  49. Front Cell Infect Microbiol. 2013 Sep 18;3:52 - PubMed
  50. Nat Immunol. 2002 Feb;3(2):196-200 - PubMed
  51. Curr Immunol Rev. 2013 Aug;9(3):129-140 - PubMed
  52. J Clin Invest. 2012 Nov;122(11):4118-29 - PubMed
  53. J Immunol. 2013 Nov 1;191(9):4818-27 - PubMed
  54. World J Gastroenterol. 2011 Aug 28;17(32):3745-51 - PubMed
  55. J Biol Chem. 2004 Feb 27;279(9):7370-7 - PubMed
  56. Circ Res. 2001 Sep 28;89(7):E41-5 - PubMed
  57. J Exp Med. 2013 Dec 16;210(13):2903-19 - PubMed
  58. Oncogene. 2008 Jan 7;27(2):168-80 - PubMed
  59. Mucosal Immunol. 2013 May;6(3):451-63 - PubMed
  60. Int Immunol. 2005 Jan;17(1):1-14 - PubMed
  61. Int J Clin Lab Res. 1996;26(3):207-10 - PubMed
  62. Trends Cell Biol. 2014 May;24(5):313-20 - PubMed
  63. Dig Liver Dis. 2008 Jul;40(7):504-9 - PubMed
  64. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 - PubMed
  65. Trends Immunol. 2013 Aug;34(8):379-89 - PubMed
  66. J Biol Chem. 2009 Sep 4;284(36):24035-48 - PubMed
  67. Int J Cancer. 2008 Dec 1;123(11):2644-50 - PubMed
  68. Cancer Res. 2005 Jun 15;65(12):5009-14 - PubMed
  69. Asian Pac J Cancer Prev. 2014;15(3):1321-6 - PubMed
  70. Nat Commun. 2015 Jan 09;6:5932 - PubMed
  71. J Leukoc Biol. 2010 Jun;87(6):989-99 - PubMed
  72. Cancer Immunol Immunother. 2011 Feb;60(2):217-26 - PubMed
  73. Yonsei Med J. 2014 Sep;55(5):1165-76 - PubMed
  74. Cell. 2006 Feb 24;124(4):783-801 - PubMed
  75. Eur J Immunol. 2010 Mar;40(3):607-11 - PubMed
  76. Mol Cancer Res. 2006 Jul;4(7):437-47 - PubMed
  77. Clin Exp Metastasis. 2008;25(4):345-56 - PubMed
  78. Cell Commun Signal. 2008 Dec 04;6:10 - PubMed
  79. J Immunol. 2013 Dec 15;191(12):6084-92 - PubMed
  80. Int Rev Immunol. 2011 Feb;30(1):16-34 - PubMed
  81. Cancer Immunol Immunother. 2010 Oct;59(10):1573-82 - PubMed
  82. Oncogene. 2008 Jan 7;27(2):218-24 - PubMed
  83. Nat Rev Immunol. 2007 Mar;7(3):179-90 - PubMed
  84. Gastroenterology. 2007 Dec;133(6):1869-81 - PubMed
  85. J Immunol. 2001 Nov 15;167(10):5887-94 - PubMed
  86. J Immunol. 2003 Jan 15;170(2):795-804 - PubMed
  87. Oncogene. 2014 Jul 3;33(27):3485-95 - PubMed
  88. J Immunol. 2009 Sep 15;183(6):3634-41 - PubMed
  89. Annu Rev Immunol. 2009;27:519-50 - PubMed
  90. Clin Nutr. 2012 Feb;31(1):85-8 - PubMed
  91. Cell Div. 2010 May 17;5:14 - PubMed
  92. Br J Cancer. 2009 May 19;100(10):1589-602 - PubMed
  93. Nature. 2004 Jul 8;430(6996):213-8 - PubMed
  94. J Exp Med. 2013 Jul 29;210(8):1509-28 - PubMed
  95. Infect Immun. 2012 Aug;80(8):2956-62 - PubMed
  96. Blood Cancer J. 2013 Nov 29;3:e166 - PubMed
  97. Nature. 2006 Mar 9;440(7081):228-32 - PubMed
  98. Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14 - PubMed
  99. Part Fibre Toxicol. 2013 Aug 13;10 :39 - PubMed
  100. Front Immunol. 2014 Jul 23;5:352 - PubMed
  101. J Immunol. 2005 May 15;174(10):6416-23 - PubMed
  102. Annu Rev Immunol. 2009;27:229-65 - PubMed
  103. Blood. 2007 Sep 15;110(6):1970-81 - PubMed
  104. Eur J Immunol. 2008 Jun;38(6):1533-47 - PubMed
  105. Semin Immunol. 2009 Aug;21(4):242-53 - PubMed
  106. Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3793-8 - PubMed
  107. Front Oncol. 2012 May 30;2:46 - PubMed
  108. Clin Cancer Res. 2013 Mar 15;19(6):1340-6 - PubMed
  109. Oncogene. 2008 Jan 7;27(2):234-43 - PubMed
  110. Oncoimmunology. 2014 Jan 1;3(1):e27763 - PubMed
  111. Ageing Res Rev. 2015 Nov;24(Pt A):29-39 - PubMed
  112. Nat Rev Drug Discov. 2012 Aug;11(8):633-52 - PubMed
  113. Cancer Sci. 2010 Apr;101(4):1014-23 - PubMed
  114. Breast Cancer Res Treat. 2012 Apr;132(2):411-9 - PubMed
  115. J Exp Med. 2003 Feb 17;197(4):403-11 - PubMed
  116. Exp Mol Med. 2014 Jan 31;46:e74 - PubMed
  117. Curr Rheumatol Rep. 2011 Apr;13(2):160-6 - PubMed
  118. Infect Immun. 2010 Jan;78(1):468-76 - PubMed
  119. Shock. 2006 Aug;26(2):174-9 - PubMed
  120. Biochem Soc Trans. 2003 Jun;31(Pt 3):637-42 - PubMed
  121. PLoS One. 2014 Oct 31;9(10):e110569 - PubMed
  122. Mol Cancer. 2012 Nov 23;11:87 - PubMed
  123. J Biol Chem. 2014 Dec 19;289(51):35237-45 - PubMed
  124. Methods Enzymol. 2009;460:105-21 - PubMed
  125. Nat Immunol. 2009 Mar;10 (3):241-7 - PubMed
  126. Front Immunol. 2014 Jul 22;5:336 - PubMed
  127. Anticancer Res. 2009 Nov;29(11):4751-8 - PubMed
  128. Cancer Cell. 2008 Nov 4;14(5):408-19 - PubMed
  129. J Exp Med. 2012 Aug 27;209(9):1671-87 - PubMed
  130. Nat Immunol. 2008 Aug;9(8):857-65 - PubMed
  131. J Exp Med. 1999 May 17;189(10):1631-8 - PubMed
  132. J Cell Biol. 2009 Oct 5;187(1):61-70 - PubMed
  133. Methods Mol Biol. 2014;1102:537-52 - PubMed
  134. Cell Death Differ. 2012 Aug;19(8):1390-7 - PubMed
  135. Nat Immunol. 2009 Jun;10(6):587-94 - PubMed
  136. Trends Mol Med. 2007 Nov;13(11):460-9 - PubMed
  137. Exp Cell Res. 2012 Nov 15;318(19):2520-30 - PubMed
  138. J Immunol. 2002 Jul 1;169(1):469-75 - PubMed
  139. Hepatology. 2002 Dec;36(6):1498-508 - PubMed
  140. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):862-6 - PubMed
  141. J Transl Med. 2006 Nov 10;4:48 - PubMed
  142. Biochem J. 2011 Sep 15;438(3):e5-6 - PubMed
  143. Mediators Inflamm. 2010;2010:674363 - PubMed

Publication Types